Dreismann Heinrich

SEC source: 0001379372-26-000002 · wk-form4_1780691103.xml · nonDerivative · entry 1

Dreismann Heinrich · CIK 0001379372 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 231,145

F1 · shares: Consists of restricted stock units granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders following such grant.

SEC source: 0001213900-26-018502 · ownership.xml · nonDerivative · entry 1

Dreismann Heinrich · CIK 0001379372 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,700

F1 · price: Grant of restricted shares under Mainz Biomed N.V. 2025 Omnibus Incentive Plan; no cash consideration paid.

F2 · balance_after: 19,700 employee stock options were granted and previously reported on a Form 3 filed January 26, 2026.

SEC source: 0001628280-25-029981 · wk-form4_1749240341.xml · nonDerivative · entry 1

Dreismann Heinrich · CIK 0001379372 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 171,444

F1 · shares: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one share of common stock and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders following such grant.

SEC source: 0001379372-24-000002 · wk-form4_1725918488.xml · nonDerivative · entry 1

Dreismann Heinrich · CIK 0001379372 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 121,648

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.02 to $27.13, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001628280-24-027334 · wk-form4_1717793673.xml · nonDerivative · entry 1

Dreismann Heinrich · CIK 0001379372 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 131,648

F1 · kind: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests upon the earlier of (a) the first anniversary of the date of grant and (b) the date of the next annual meeting of stockholders following such grant.

SEC source: 0001209191-23-036374 · doc4.xml · derivative · entry 1

Dreismann Heinrich · CIK 0001379372 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,466

Underlying: Common Stock · 5,466 shares

Expires 2033-06-09

F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest monthly over one year from the vesting commencement date.

SEC source: 0001379372-23-000002 · wk-form4_1685743492.xml · nonDerivative · entry 1

Dreismann Heinrich · CIK 0001379372 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 115,953

F1 · kind: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests upon the earlier of (a) the first anniversary of the date of grant and (b) the date of the next annual meeting of stockholders following such grant.

F2 · balance_after: The Reporting Person made prior Section 16 filings under CIK 0001471714

SEC source: 0001209191-23-031639 · doc4.xml · derivative · entry 1

Dreismann Heinrich · CIK 0001379372 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 190,000

Underlying: Common Stock · 190,000 shares

Expires 2033-05-19

F1 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest monthly over three years from the grant date.

SEC source: 0001628280-22-016216 · wf-form4_165429152058899.xml · nonDerivative · entry 1

Dreismann Heinrich · CIK 0001379372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,802

F1 · kind: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests upon the earlier of (a) the first anniversary of the Date of Grant and (b) the date of the next annual meeting of stockholders following such grant.

SEC source: 0001209191-18-009141 · doc4.xml · derivative · entry 6

Dreismann Heiner · CIK 0001379372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires 2027-06-12

F1 · derivative.exercise_date: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger"). In connection with the Merger, this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option.

SEC source: 0001209191-18-009141 · doc4.xml · derivative · entry 5

Dreismann Heiner · CIK 0001379372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2026-06-12

F1 · derivative.exercise_date: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger"). In connection with the Merger, this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option.

SEC source: 0001209191-18-009141 · doc4.xml · derivative · entry 4

Dreismann Heiner · CIK 0001379372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2026-03-09

F1 · derivative.exercise_date: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger"). In connection with the Merger, this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option.

SEC source: 0001209191-18-009141 · doc4.xml · derivative · entry 3

Dreismann Heiner · CIK 0001379372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 24,000 shares

Expires 2023-12-16

F1 · derivative.exercise_date: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger"). In connection with the Merger, this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option.

SEC source: 0001209191-18-009141 · doc4.xml · derivative · entry 2

Dreismann Heiner · CIK 0001379372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2023-09-09

F1 · derivative.exercise_date: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger"). In connection with the Merger, this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option.

SEC source: 0001209191-18-009141 · doc4.xml · derivative · entry 1

Dreismann Heiner · CIK 0001379372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,666 shares

Expires 2022-02-01

F1 · derivative.exercise_date: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger"). In connection with the Merger, this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option.

SEC source: 0001209191-17-040963 · doc4.xml · derivative · entry 1

Dreismann Heiner · CIK 0001379372 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2027-06-12

F1 · derivative.exercise_date: The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant (6/13/2018), or the next annual meeting of the stockholders, if earlier, subject to the reporting person's continued service to the Issuer through such vesting date.